• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Savara Inc (NQ: SVRA )

    4.175 +0.215 (+5.43%)
    Streaming Delayed Price Updated: 3:45 PM EDT, Aug 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 610,318
    Open 3.960
    Bid (Size) 4.170 (6)
    Ask (Size) 4.180 (11)
    Prev. Close 3.960
    Today's Range 3.920 - 4.250
    52wk Range 3.115 - 5.700
    Shares Outstanding 114,066,080
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
    From Savara Inc.
    Via Business Wire
    Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
    Savara announces Phase 3 IMPALA-2 trial results for molgramostim in treating autoimmune pulmonary alveolar proteinosis. The inhaled GM-CSF met primary and secondary endpoints, showing significant... 
    Via Benzinga

    Performance

    YTD
    -4.46%
    -4.46%
    1 Month
    -8.64%
    -8.64%
    3 Month
    -15.66%
    -15.66%
    6 Month
    -11.36%
    -11.36%
    1 Year
    +14.07%
    +14.07%

    More News

    Read More
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    SVRA Stock Earnings: Savara Misses EPS for Q1 2024
    Via InvestorPlace
    SVRA Stock Earnings: Savara Beats EPS for Q4 2023
    Via InvestorPlace
    Savara Inc. (NASDAQ: SVRA) Making Surprising Moves in Monday Session
    Via Investor Brand Network
    Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    From Savara Inc.
    Via Business Wire
    Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    From Savara Inc.
    Via Business Wire
    3 Penny Stocks Poised for Major Upside Over the Next 5 Years
    Via InvestorPlace
    3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
    Via InvestorPlace
    Savara to Present at the Jefferies Global Healthcare Conference
    From Savara Inc.
    Via Business Wire
    Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
    From Savara Inc.
    Via Business Wire
    Savara Announces New Employment Inducement Grant
    From Savara Inc.
    Via Business Wire
    Savara Reports First Quarter 2024 Financial Results and Provides Business Update
    From Savara Inc.
    Via Business Wire
    Savara to Present at the Citizens JMP Life Sciences Conference
    From Savara Inc.
    Via Business Wire
    Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
    From Savara Inc.
    Via Business Wire
    Savara Announces New Employment Inducement Grant
    From Savara Inc.
    Via Business Wire
    Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
    From Savara Inc.
    Via Business Wire
    Savara to Present at the Barclays 26th Annual Global Healthcare Conference
    From Savara Inc.
    Via Business Wire
    Savara Announces New Employment Inducement Grant
    From Savara Inc.
    Via Business Wire
    Savara to Present at Two Upcoming Healthcare Conferences
    From Savara Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    From Savara Inc.
    Via Business Wire
    Savara Added to the NASDAQ Biotechnology Index
    From Savara Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.